ADAPY
Adaptimmune Therapeutics PLC
-0.00 (-4.40%)0.02USD18.5K成交股數38.0M市值–本益比(近四季)0.6股價營收比-89.3%營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 | 23Q1 | 22Q3 | 22Q2 | 22Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 13.7M+141% | 7.3M+3054% | 40.9M+459% | 128M+2400% | 5.7M-88% | 231K-97% | 7.3M+32% | 5.1M+43% | 47.6M | 7.0M | 5.5M | 3.6M |
| 營業成本 | 2.5M | 879K | – | – | – | – | – | – | – | – | – | – |
| 毛利 | 11.2M | 6.4M | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | 81.7% | 87.9% | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 23.0M | 28.9M | 34.3M | 40.4M | 35.2M | 33.2M | 37.8M | 30.0M | 25.5M | 33.2M | 34.7M | 36.8M |
| 銷售管理費用 | 18.5M | 23.3M | 21.3M | 19.1M | 19.7M | 16.9M | 16.2M | 20.1M | 20.4M | 16.8M | 14.6M | 16.8M |
| 營業利益 | −30.3M-39% | −45.7M-8% | −14.7M-69% | 68.7M-253% | −49.3M-3075% | −49.9M+16% | −46.6M+7% | −44.9M-10% | 1.7M | −43.0M | −43.8M | −50.0M |
| 營業利益率 | -221.5% | -627.8% | -35.9% | 53.6% | -867.6% | -21,582.7% | -637.1% | -875.4% | 3.5% | -613.5% | -790.0% | -1,398.1% |
| 稅後淨利 | −30.3M-37% | −47.6M-1% | −17.6M-61% | 69.5M-425% | −48.5M-4782% | −47.9M+16% | −45.6M+2% | −21.4M-57% | 1.0M | −41.4M | −44.5M | −50.3M |
| 淨利率 | -221.8% | -653.2% | -43.1% | 54.2% | -854.2% | -20,743.3% | -623.0% | -416.9% | 2.2% | -591.1% | -803.9% | -1,406.0% |
| 稀釋 EPS | -0.02-33% | -0.03-25% | -0.01-67% | 0.04-300% | -0.03 | -0.040% | -0.03-40% | -0.02-60% | 0.00 | -0.04 | -0.05 | -0.05 |
| 稀釋股數 | 1.58B | 1.54B | 1.53B | 1.56B | 1.45B | 1.21B | 1.36B | 1.11B | 1.00B | 981M | 963M | 940M |
資產負債表 期末餘額
| 科目 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 | 23Q1 | 22Q3 | 22Q2 | 22Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 26.1M | 41.1M | 117M | 212M | 141M | 144M | 90.1M | 77.0M | 120M | 79.0M | 97.8M | 89.5M |
| 應收帳款 | 9.3M | 4.4M | 12.5M | 2.3M | 8.4M | 821K | 789K | 3.0M | 1.7M | 1.8M | 2.4M | 1.8M |
| 存貨 | 11.4M | 11.8M | 1.9M | – | – | – | – | – | – | – | – | – |
| 總資產 | 131M | 158M | 317M | 322M | 258M | 283M | 297M | 343M | 288M | 332M | 388M | 420M |
| 有息負債 | 25.7M | 25.4M | 49.9M | 25.0M | – | – | – | – | – | – | – | – |
| 總負債 | 202M | 196M | 237M | 225M | 234M | 243M | 209M | 216M | 204M | 219M | 246M | 257M |
| 股東權益 | −71.0M | −37.4M | 80.0M | 96.3M | 24.4M | 39.5M | 88.1M | 127M | 83.9M | 113M | 142M | 163M |
| 負債比 | 154.3% | 123.7% | 74.8% | 70.1% | 90.6% | 86.0% | 70.3% | 63.1% | 70.9% | 65.9% | 63.4% | 61.1% |
| 淨現金(現金 − 有息負債) | 386K | 15.6M | 66.9M | 187M | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 | 23Q1 | 22Q3 | 22Q2 | 22Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −66.6M | – | – | −32.0M-14% | – | – | – | −37.3M | – | – | −54.4M |
| 資本支出 | – | 1.2M | – | – | 102K | – | – | – | 2.3M | – | – | 7.1M |
| 自由現金流 | – | −67.8M | – | – | −32.1M-19% | – | – | – | −39.6M | – | – | −61.5M |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -930.6% | – | – | -564.5% | – | – | – | -83.3% | – | – | -1,720.7% |
營收拆解 2024 年度 10-K 的分部揭露 · 年增對前一年度
產品／服務2024 年度 · 178M
| Development Revenue | 177M | 99.3% | +193.3% |
|---|---|---|---|
| 產品 | 1.2M | 0.7% | – |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2024 | 178M | +195.3% | −70.8M | -39.8% | -0.05 | −74.1M |
| FY2023 | 60.3M | +122.0% | −114M | -188.9% | -0.09 | −146M |
| FY2022 | 27.1M | +341.5% | −165M | -609.5% | -0.17 | −171M |
| FY2021 | 6.1M | +55.4% | −158M | -2,571.0% | -0.17 | 2.2M |
| FY2020 | 4.0M | +252.8% | −130M | -3,286.8% | -0.15 | −55.9M |
| FY2019 | 1.1M | -98.1% | −137M | -12,225.0% | -0.22 | −114M |
| FY2018 | 59.5M | – | −95.5M | -160.5% | -0.16 | −108M |